We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ocular Hypertension Treatment Study (OHTS) (OHTS)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000125
First Posted: September 24, 1999
Last Update Posted: December 16, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Eye Institute (NEI)
Information provided by (Responsible Party):
Michael Kass, Washington University School of Medicine
  Purpose

To determine whether medical reduction of intraocular pressure prevents or delays the onset of glaucomatous visual field loss and/or optic disc damage in ocular hypertensive participants judged to be at moderate risk for developing open-angle glaucoma.

To produce natural history data to assist in identifying patients at most risk for developing open-angle glaucoma and those most likely to benefit from early medical treatment.

To quantify risk factors for developing open-angle glaucoma among ocular hypertensive individuals.


Condition Intervention Phase
Ocular Hypertension Glaucoma Drug: Topical ocular hypotensive eye drops. Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Ocular Hypertension Treatment Study (OHTS)

Resource links provided by NLM:


Further study details as provided by Michael Kass, Washington University School of Medicine:

Primary Outcome Measures:
  • Incidence of Primary Open-Angle Glaucoma in Hypotensive Patients [ Time Frame: 5 yrs (OHTS I, June 2002) and 13.0 yrs (completion of both phases of OHTS, March 2009) ]
    Comparison of the cumulative proportion of participants who develop primary open-angle glaucoma in the observation and medication groups.


Enrollment: 1636
Study Start Date: February 1994
Estimated Study Completion Date: March 2020
Primary Completion Date: June 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Observation
Close Observation.
Treatment
Participants treated with commercially available topical ocular hypotensive eye drops.
Drug: Topical ocular hypotensive eye drops.
Topical ocular hypotensive eye drops.

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Men and nonpregnant women between the ages of 40 and 80 with IOP greater than or equal to 24 mm Hg but less than or equal to 32 mm Hg in at least one eye and IOP greater than or equal to 21 but less than or equal to 32 mm Hg in the fellow eye, as well as normal visual fields and optic discs are eligible for the trial. Patients presenting with best-corrected visual acuity worse than 20/40 in either eye, previous intraocular surgery, a life-threatening or debilitating disease, secondary causes of elevated IOP, angle-closure glaucoma or anatomically narrow angles, other diseases that can cause visual field loss, background diabetic retinopathy, optic disc abnormalities that can produce visual field loss or obscure the interpretation of the optic disc, or unwillingness to undergo random assignment are excluded from the trial.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000125


Sponsors and Collaborators
Washington University School of Medicine
National Eye Institute (NEI)
Investigators
Study Chair: Michael A Kass, MD Washington University Department of Ophthalmology and Visual Sciences
  More Information

Additional Information:
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Michael Kass, Professor, Ophthalmology and Visual Sciences, Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT00000125     History of Changes
Other Study ID Numbers: NEI-24
5U10EY009307-16 ( U.S. NIH Grant/Contract )
5U10EY009341-14 ( U.S. NIH Grant/Contract )
First Submitted: September 23, 1999
First Posted: September 24, 1999
Results First Submitted: March 6, 2015
Results First Posted: March 19, 2015
Last Update Posted: December 16, 2016
Last Verified: December 2016

Additional relevant MeSH terms:
Hypertension
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Ophthalmic Solutions
Tetrahydrozoline
Antihypertensive Agents
Pharmaceutical Solutions
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nasal Decongestants
Vasoconstrictor Agents
Respiratory System Agents